Prostate cancer: the value of combined urinary T2:ERG and PCA3 testing

Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Weiterlesen? Jetzt anmelden!
  • Combined urinary testing for the 2 prostate cancer (PCa)-associated RNA markers, T2:ERG and PCA3, improved specificity of predicting aggressive PCa compared with prostate-specific antigen (PSA). 
  • 42% of unnecessary prostate biopsies would have been averted by using combined urinary testing.

Why this matters

  • Serum PSA has low specificity for detecting aggressive PCa at PSA levels that have sufficient sensitivity. 
  • Combined T2:ERG and PCA3 testing can avert unnecessary biopsy while retaining robust sensitivity for detecting aggressive PCa, which offers potential healthcare cost savings.

Study design

  • Urinary RNA parameters that improve specificity for predicting PCa were identified in the developmental cohort (n=516) and confirmed in a validation cohort (n=561).
  • Funding: NIH.

Key results